Baricitinib Mono vs Combo: 6-Year RA Data
January 13, 2026
-
3 min
A 6-year observational study evaluated the effectiveness of baricitinib for rheumatoid arthritis (RA), comparing monotherapy to its use with methotrexate. Conducted on 219 patients at a tertiary center between 2017 and 2023, the study showed both treatment strategies produced rapid disease activity reduction with similar long-term outcomes. Notably, 33% of patients achieved Boolean remission and long-term drug survival was comparable between groups. The findings suggest baricitinib monotherapy is a viable alternative when methotrexate is unsuitable, with a focus on individualized treatment plans. Lead author Dr. Sara Bayat underscores the importance of further randomized trials to establish efficacy.
1. Study followed 219 RA patients initiating baricitinib. 2. Evaluated effects of monotherapy versus combination therapy with methotrexate. 3. 33% achieved boolean remission at least once. 4. Similar drug survival observed in both groups over 72 months. 5. Safety profile consistent with known baricitinib risks. 6. Individualization of treatment is crucial, especially regarding methotrexate tolerance. 7. Further randomized trials needed to confirm findings.
Listen Tab content
